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686Objectives: Chronic lung disease is a significant comorbidity in patients undergoing cardiac surgery. Chronic
lung disease is currently being classified and reported to the Society of Thoracic Surgeons database by using either
clinical interview or spirometric testing. We sought to compare the chronic lung disease classification captured by
the 2 methods.
Methods:We performed a prospectively designed study in which patients presenting for cardiac surgery, exclud-
ing emergent patients, were screened for a history of asthma, a history of 10 or more pack-years of smoking,
a persistent cough, and the use of oxygen. Each selected patient underwent spirometry. The presence and severity
of chronic lung disease was coded per Society of Thoracic Surgeons guidelines by using the 2 methods of clinical
report and spirometric results. The chronic lung disease classifications were compared, and differences were de-
termined by using concordance and discordance rates. The results were then used to construct Society of Thoracic
Surgeons–predicted risk models.
Results: The discordant rate was 39.1%, with underestimation of the severity of chronic lung disease in 94% of
misclassified patients. This affected the Society of Thoracic Surgeons–predicted risk models for prolonged ven-
tilation, morbidity/mortality, and mortality by increasing the predicted risk when spirometry was used for mor-
bidity/mortality by an average of 1.5  1.2 percentage points (P< .001) and prolonged ventilation time by an
average of 1.3  1.4 percentage points (P< .001).
Conclusion: The use of patient history for symptoms, medication, and/or oxygen use as the only method to
determine chronic lung disease for this subgroup of patients led to underreporting of chronic lung disease and
underestimation of the risk for adverse outcomes. Therefore data submission to the Society of Thoracic Surgeons
database should be designed to capture and correct for potential bias in the definition of chronic lung disease
because the rate of spirometry in different centers in defining chronic lung disease is not regulated. (J Thorac
Cardiovasc Surg 2010;139:686-91)Chronic obstructive pulmonary disease (COPD) is a leading
cause of morbidity and mortality in the United States1 and is
often underdiagnosed not only in its early stages but also
when there is severe impairment of lung function. The diag-
nosis of COPD or chronic lung disease (CLD) historically
has depended on the presence of symptoms. Recent guide-
lines for the diagnosis of pulmonary disease use lung func-
tion measurements to diagnose and classify disease
severity.2-4 Unfortunately, lung function measurements are
infrequently performed by primary care physicians. Duringe Department of Cardiac Surgery Research,a Inova Heart and Vascular
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The Journal of Thoracic and Cardiovascular Surgthe year 2000, an estimated 10 million adults in the United
States reported ‘‘physician-diagnosed COPD.’’4,5 A contem-
poraneous survey using lung function measurements resulted
in a prevalence estimate of 23.6 million adults with COPD.6,7
Because cigarette smoking is a shared risk for cardiovascu-
lar and pulmonary disease, cardiac surgery is often performed
on subjects with lung disease. Several reports have deter-
mined that the incidence of CLD in patients undergoing cor-
onary artery bypass grafting can range from 4% to 27%.
More importantly,CLD is recognized as a significant risk fac-
tor formortality andmorbidity in patients undergoing cardiac
surgery.8-11 Data obtained from spirometry provide
information beyond the diagnosis of CLD. A large popula-
tion-based study found that even small decrements in lung
function in a restrictive pattern can be associated with under-
lying heart disease and are associatedwith an increased risk of
death (hazard ratio, 1.7; 95% confidence interval, 1.4–2.0).12
The Society of Thoracic Surgeons’ (STS) risk algorithms
for determining 30-day operative mortality and morbidity
risk and prolonged ventilation for patients undergoing car-
diac surgery do not require spirometry to define theery c March 2010
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CLD ¼ chronic lung disease
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Mpresence, severity, or both of CLD. In general, because there
is a gross underuse of spirometry, it is likely that across cen-
ters submitting data to the STS on the rate and severity of
CLD, their respective reports are based on different methods
of assessment and use of spirometry. We found that before
this study less than 2% of our patients underwent spiromet-
ric testing before surgical intervention, and we assume other
centers reporting data to the STS will have similar findings.
Therefore assessment of CLD is vital to accurately predict
expected outcomes in patients undergoing cardiac surgery,
especially in the new era in which the prediction models
of outcomes are so thoroughly assessed by the different or-
ganizations.
The purposes of the study were (1) to determine whether
preoperative spirometric measures provide a better parame-
ter in identifying the presence, severity, or both of CLD ac-
cording to the STS definition compared with an assessment
that is dependent on patient self-report for symptoms, med-
ication, and/or home oxygen therapy; (2) to determine
whether the use of spirometry in the identification of CLD
has an effect on the STS-predicted risk models for prolonged
ventilation, mortality, and morbidity; and (3) to determine
whether our findings justify a review of the current method
of capturing CLD data and a better control of the different
methods used in identifying and classifying CLD and its re-
spective potential bias on the STS risk score.
MATERIALS AND METHODS
Design
This was a prospective study. The intent was to ‘‘case find’’ patients who
were at high risk for having lung disease; therefore each patient who pre-
sented for cardiac surgery, excluding emergent patients, were screened for
a history of asthma, history of 10 pack-years or more of smoking, and/or
a persistent cough (a cough lasting 4 weeks). The study was reviewed
and approved by our institutional review board.
After a patient was identified as meeting the inclusion criteria, spirometry
was performed before surgical intervention. The spirometric testing was ad-
ministered under the American Thoracic Society (ATS) and European Re-
spiratory Society (ERS) standard guidelines for spirometric testing.2,3,13,14
The spirometric results were reviewed by a board-certified pulmonologist
after first coding patients based on their self-report of medication, oxygen
use, or both. The pulmonologist then recoded the patient’s CLD, if any,
by using the spirometric results according to the STS guidelines. The data
from each CLD classification were compared. Other patient variables col-
lected included age, sex, type of operation, length of hospital and intensiveThe Journal of Thoracic and Cacare unit stay, time to extubation, and postoperative complications. These
were collected from the hospital’s local inpatient STS database. In addition,
patients were excluded from the analysis if their spirometric results were
considered uninterruptible, as defined by the ATS/ERS task force.2,3,13,14
Clinical Definitions
Spirometry is the most common, widely available, and reproducible pul-
monary function test that measures the volume of air inhaled and exhaled
from the lungs over time.2,3,13,14 Two machines were used to assess spiro-
metric results before surgical intervention: inpatient (SpiroPro; SensorMed-
ics, Yorba Linda, Calif) and outpatient (Puritan Bennett Renaissance II;
Puritan Bennett, Boulder, Colo). Both machines met the ATS/ERS stan-
dards.2,3,13,14 Spirometric testing was performed within 2 weeks of surgical
intervention (median, 2.0 days).
CLD according to the STS standards was staged on the following defini-
tions: (1) none, no medications or forced expiratory volume in 1 second
(FEV1) greater than 75% of predicted value; (2) mild, patient taking chronic
inhaled or oral bronchodilator therapy or FEV1 60% to 75% of percent pre-
dicted value; (3) moderate, patient taking chronic steroid therapy or FEV1
50% to 59% of percent predicted value; or (4) severe, home oxygen or
room air PO2 of less than 60 or room air pCO2 of greater than 50 or FEV1
less than 50% of percent predicted value.15-17
Sample Size
The total number of patients required for the study to have a nominal
power of 80%, a test proposition of 20%, and an underlying undercoding
prevalence of 10%was 294. However, a preliminary analysis demonstrated
that the underreporting of CLD by using clinical definitions without spirom-
etry was greater than 40%, which would require a sample size of 50 or more
to retain a nominal power of 80%.
Statistical Analysis
Continuous data are presented as means standard deviations. Categor-
ical data are presented as frequencies and percentages. Statistical compari-
sons were accomplished bymeans of 1-way analysis of variance, the c2 test,
or the Fisher’s exact test, where appropriate. The rate of misclassification
was determined by using concordance and discordance rates (referent vari-
ant analysis). Lastly, after spirometric results were obtained, predicted STS
risks models for prolonged ventilation, morbidity/mortality, and mortality
for patients undergoing coronary artery bypass grafting surgery were subse-
quently recalculated with the new spirometry-designated classification.
Both original STS-predicted risk models and recalculated models based
on spirometric results were then compared and displayed. The STS risk
model was developed and validated as a risk-adjustment methodology for
the control of potential confounding variables.15-17 All analyses were con-
ducted with SAS software (version 9.1; SAS Institute, Inc, Cary, NC).RESULTS
From October 2007 to October 2008, 220 patients met the
inclusion criteria for the study and represented 23.3% of the
patientswhowere operated on by us using the heart–lungma-
chine during this period. Patients were classified into groups
based on their respective spirometric results. Table 1 displays
the patients’ demographics and clinical characteristics over-
all and by group. Regardless of classification, the average age
was 64.9 (SD, 10.9) years, 78% of the patients were male,
and 10% were current smokers. Patients in the severe group
were significantly older (68  10.1 years) and had a signifi-
cant decrease in their FEV1 percent predicted values (45.0%
 13.1%) when compared with the other groups.rdiovascular Surgery c Volume 139, Number 3 687
TABLE 1. Patient demographics and clinical characteristics by STS group (postspirometric classification)
Total spirometry
group (n ¼ 220)
No CLD
(n ¼ 103)
Mild CLD
(n ¼ 62)
Moderate CLD
(n ¼ 21)
Severe CLD
(n ¼ 28) P value
Age (y) 64.5  10.9 62.1  9.7 66.9  12.1 66.0  11.2 68.0  10.1 .010
Ejection fraction (%) 51.6  13.6 53.7  12.4 48.9  15.8 49.8  14.7 50.3  12.0 .145
Body mass index (kg/m2) 29.2  6.0 29.6  6.3 28.4  5.3 28.3  4.5 29.4  7.0 .564
FEV1 (%) 75.3  24.5 88.2  23.0 72.4  25.0 54.1  8.7 45.0  13.1 <.001
FVC (%) 84.3  46.4 96.3  58.8 82.4  32.3 61.3  8.6 64.3  20.9 .001
Male sex 171 (77.7) 86 (83.5) 47 (75.8) 15 (71.4) 20 (71.4) .360
NYHA class (III or IV) 47 (21.4) 13 (12.6) 17 (27.4) 7 (33.3) 9 (32.1) .914
Currently smoking 22 (10.0) 2 (1.9) 4 (6.4) 3 (14.3) 1 (3.6) .086
Family history of CAD 138 (62.7) 65 (63.1) 36 (58.1) 15 (71.4) 18 (64.3) .736
Diabetes 74 (33.8) 30 (29.1) 20 (32.2) 6 (28.6) 12 (42.8) .572
History of renal failure 5 (2.3) 3 (2.9) 1 (1.6) 1 (4.8) 0 (0) .686
CLD (severe) 28 (12.7) 0 (0) 0 (0) 0 (0) 28 (100) <.001
CVA 16 (7.3) 3 (2.9) 5 (8.1) 5 (23.8) 3 (10.7) .008
Myocardial infarction 15 (6.8) 6 (5.8) 5 (8.1) 3 (14.3) 1 (3.6) .473
Hypercholesterolemia 21 (9.5) 7 (6.8) 8 (12.9) 4 (19.0) 2 (7.1) .267
Hypertension 175 (79.5) 79 (76.7) 49 (79.0) 17 (80.9) 24 (85.7) .772
Peripheral vascular disease 39 (17.7) 14 (13.6) 14 (22.6) 3 (14.3) 7 (25.0) .339
Cerebrovascular disease 36 (16.4) 10 (9.7) 13 (21.0) 8 (38.1) 4 (14.3) .008
Previous valve 2 (0.9) 0 (0) 0 (0) 1 (4.8) 1 (3.6) .072
Previous CABG 4 (1.8) 2 (1.9) 0 (0) 1 (4.8) 1 (3.6) .465
Elective 98 (44.5) 45 (43.7) 33 (53.2) 7 (33.3) 10 (35.7) .278
Values are presented as means (standard deviations) and numbers (percentages), where shown. Six patients were missing values. STS, Society of Thoracic Surgeons; CLD, chronic
lung disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; NYHA, New York Heart Association; CAD, coronary artery disease; CVA, cerebrovascular
accident; CABG, coronary artery bypass grafting.
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The STS database guidebook definitions were used to de-
termine perioperative complications.17 Twenty (9.1%) pa-
tients had a prolonged ventilation time, 8 (3.6%) patients
had pneumonia, 68 (30.9%) patients had lengths of stay
greater than 7 days, and 3 (1.4%) patients died within 30
days of surgical intervention. Statistically significant differ-
ences were noted for the following variables: transient
stroke, prolonged ventilation time, pneumonia, length of
stay greater than 7 days, 30-day mortality, and readmission
at 30 days or less after the operation. However, the real clin-
ical significance might need to be tested with a larger cohort
of patients (Table 2).
Spirometric Findings
One hundred ninety-two patients had interpretable spiro-
metric results. Seventy-five of the 192 patients were found to
be misclassified/discordant, resulting in an overall discor-
dant rate of 39.1%. The severity of CLD was underesti-
mated in 71 (94.7%) of the 75 misclassified patients.
Table 3 displays the number of patients misclassified for
each category of CLD, as defined by the STS. More than
44% of the patients in the mild CLD category based on clin-
ical evaluation were misclassified when the spirometric re-
sults were obtained.
Table 4 compares the STS-predicted risk models for pro-
longed ventilation, morbidity/mortality, and mortality with
and without the use of spirometry. The predicted risk for688 The Journal of Thoracic and Cardiovascular Surgany one of the 3 modeled complications was significantly
higher when calculated with spirometry rather than clinical
assessment for the standard STS definition. The greatest ef-
fect was observed for composite morbidity/mortality, with
an average increase in predicted risk of 1.5  1.2 (P<
.001) percentage points when spirometric information was
used. Clinical diagnosis also underestimated the risk of pro-
longed ventilation time by an average of 1.3 1.4 (P<.001)
percentage points (Figure 1).
DISCUSSION
In this study we set out to determine whether the use of
spirometric measures in a subset of patients undergoing car-
diac surgery before the surgical intervention would provide
a better parameter in determining the presence, severity, or
both of CLD when compared with clinical classification
based on STS definitions for CLD. Our findings suggest
there is a significant underestimation of the prevalence and
severity of CLDwhen using the STS definitions without spi-
rometry. The greatest disparity was seen among patients
who would have been classified as having either no or
mild disease when, in fact, severe disease was detected in
more than 12% of these patients.
In addition, the purpose of this study was to determine the
effect, if any, on the STS-predicted risk models for pro-
longed ventilation, mortality, and morbidity. We did find
that the use of spirometry affected the aforementioned STS
risk models. This study determined that the use ofery c March 2010
TABLE 2. Perioperative complication rates by STS group (postspirometric classification)
Total spirometry
group (n ¼ 220)
No CLD
(n ¼ 103)
Mild CLD
(n ¼ 62)
Moderate CLD
(n ¼ 21)
Severe CLD
(n ¼ 28) P value
Transient stroke 1 (0.5) 0 (0) 0 (0) 1 (4.8) 0 (0) .026
Permanent stroke 4 (1.8) 2 (1.9) 1 (1.6) 0 (0) 0 (0) .820
Septicemia 1 (0.5) 0 (0) 1 (1.6) 0 (0) 0 (0) .487
Mediastinitis 1 (0.5) 0 (0) 0 (0) 0 (0) 1 (3.6) .083
Cardiac tamponade 2 (0.9) 1 (1.0) 0 (0) 0 (0) 0 (0) .785
Prolonged ventilator time 20 (9.1) 4 (3.9) 8 (12.9) 0 (0) 7 (25.0) .001
Pneumonia 8 (3.6) 0 (0.0) 3 (4.8) 1 (4.8) 4 (14.3) .004
Renal failure 15 (6.8) 5 (4.8) 6 (9.7) 1 (4.8) 2 (7.1) .664
Dialysis required 3 (1.4) 1 (1.0) 1 (1.6) 0 (8) 1 (3.6) .707
Reoperation for bleeding 2 (0.9) 0 (0) 1 (1.6) 1 (4.8) 0 (0) .184
Atrial fibrillation 22 (10.0) 10 (9.7) 7 (11.3) 1 (4.8) 3 (10.7) .856
Length of stay 7 d 68 (30.9) 18 (17.4) 21 (33.9) 10 (47.6) 17 (60.7) <.001
30-d Mortality 3 (1.4) 0 (0) 1 (1.6) 0 (0) 2 (7.1) .037
Readmission 30 d 15 (6.8) 7 (6.8) 2 (3.2) 0 (0) 6 (21.4) .007
STS, Society of Thoracic Surgeons; CLD, chronic lung disease.
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Mspirometry in the risk models created an underreporting of
the expected number of adverse outcomes to include death
by 2% to 25% depending on the degree of CLD severity
identified.
This underreporting suggests that the current STS method
of defining CLD might not be adequate. Having the option
of using a clinical diagnosis versus spirometry might not
be enough because the STS currently does not provide
models that incorporate clinical diagnosis–only or spirome-
try-only models. Therefore it is apparent that the STS needs
to address how best to capture CLD data or adjust for the
method used to identify CLD so that the STS-predicted
risk models can be correctly calculated, applied, and inter-
preted for a given patient population and across cardiac sur-
gery centers.TABLE 3. Cross-tabulation of clinical versus spirometric assessment (n ¼
No CLD M
Clinical assessment No CLD 96
Mild CLD 2
Moderate CLD 1
Severe CLD 0
Total 99
Concordance rate: 60.9%, (117/192)
Discordance rate: 39.1%, (75/192)
Underestimation by STS definition: 94.6% (71/75)
Overestimation by STS definition: 5.4% (4/75)
Misclassification rate by prespirometric STS class
No CLD 56/152 (36.8%)
Mild CLD 16/36 (44.4%)
Moderate CLD 2/2 (100.0%)
Severe CLD 1/2 (50.0%)
*Twenty-eight patients were given diagnoses of ‘‘unknown’’ based on American Thoracic
The Journal of Thoracic and CaFurthermore, the correct calculation of the risk models
carries significance beyond the immediate postoperative
period of time. In this era of tying compensation to out-
come, there is increased accountability for the health pro-
fessional. Having correctly calculated predicted risk
models can be imperative to the success of a cardiac sur-
gery program.18,19
Another relevant concern we had in the design of our
study was the increased cost associated with additional test-
ing before surgical intervention, even a relatively small one.
This was one reason why we designed the study to ‘‘case
find’’ patients with a higher risk for CLD who most likely
would benefit from early intervention, especially patients
with severe disease. The true effect of early intervention
on patients identified with a certain level of impairment192)*
Spirometric assessment
ild CLD Moderate CLD Severe CLD Total
33 11 12 152
20 5 9 36
0 0 1 2
1 0 1 2
54 16 23 192 *
Society guidelines. CLD, Chronic lung disease; STS, Society of Thoracic Surgeons.
rdiovascular Surgery c Volume 139, Number 3 689
TABLE 4. Average values for STS-predicted risk models with and
without spirometry
Total spirometry
group (n ¼ 192)
Prolonged ventilation
time
STS without spirometry 5.5  4.4 —
STS with spirometry 6.8  5.8 P< .001
Mortality STS without spirometry 1.1  1.3 —
STS with spirometry 1.3  1.8 P< .001
Morbidity/mortality STS without spirometry 8.9  6.1 —
STS with spirometry 10.4  7.3 P< .001
STS, Society of Thoracic Surgeons.
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scope of this study. However, we did show that the use of
spirometry is important when determining CLD in a subset
of patients so that more in-depth assessment can take place.
A further area of exploration should focus on the consid-
eration of using the ATS/ERS guidelines in determining
CLD rather than the current definitions. A strength of the
ATS/ERS guidelines is that they provide for 2 different
types of ventilatory defects: obstructive and restrictive ab-
normalities. An obstructive abnormality is defined as an
FEV1/forced vital capacity (FVC) of less than the fifth per-
centile of the predicted value. A restrictive abnormality is
defined as an FVC reduction to less than the fifth percentile
of the predicted value and a normal FEV1/FVC ratio.
14 Per-
haps thought should be given to incorporating both FEV1
and FVC, if not the diffusion capacity of the lung for carbon
monoxide, when determining CLD.2,3,13,14FIGURE 1. Clinical and spirometric comparison of the Society of Thoracic Su
morbidity, and operative mortality.
690 The Journal of Thoracic and Cardiovascular SurgLimitations of the Current Study and Analysis
Spirometry was only performed in subjects with a history
of asthma, a 10 pack-year or greater smoking history, or
a chronic cough. By focusing only on this cohort of patients,
we might have missed some patients with abnormal spiro-
metric results. Also, restriction on the use of spirometry
only might represent factors other than intrinsic pulmonary
disease, such as neuromuscular weakness, congestive heart
failure, pleural effusions, and obesity.
In addition, the study design (preselecting patients at
a higher risk for CLD) might have a potential for work-up
bias. Work-up bias was originally described by Ransohoff
and Feinstein20 in the late 1970s, when they wrote about in-
herent biases in diagnostic testing. More recently, Black-
stone and Lauer,21 in their 2004 editorial for the Journal
of Thoracic and Cardiovascular Surgery, discussed the
treachery of work-up bias and the generalizability of inves-
tigators’ findings. They described work-up bias as ‘‘ .oc-
curs whenever a test is performed and a gold standard
(reference) validation is not performed for each patient,
and accuracy of the test is reported for only patients with ref-
erence validation.’’ We did not correct for any bias that
might be introduced in our findings.
CONCLUSION
The findings of this study suggest that the presence and
severity of CLDmight be significantly underreported in a co-
hort of patients (10 pack-year smoking history, asthma, or
a persistent cough) when using only the STS definitions
without spirometry. The underreporting/misclassificationrgeons–predicted risk models for prolonged ventilation time, mortality and
ery c March 2010
Ad et al Perioperative Managementled to a perceived decrease in the risk for adverse outcomes.
This study found that when the STS definitions with spirom-
etry were used to determine CLD, the predicted risk models
for prolonged ventilation, morbidity/mortality, andmortality
were significantly adversely changed. This adverse change
can have a significant effect on composite risk stratification
scoring for cardiac surgery programs. Consideration should
be given to using spirometric testing when determining CLD
in a cohort of patients. Further study should be undertaken to
determine whether all patients presenting for cardiac surgery
should undergo spirometry and how the STS should define,
adjust for, or both the method used to identify CLD.P
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